6 ms·
Drug Development Failure: how GLP-1 development was abandoned in 1990
- tiahura 2y agoIn 1990, Pfizer and CalBio subsidiary MetaBio abandoned GLP-1 drug development despite showing efficacy and holding patents. Pfizer misjudged the market for injectable diabetes drugs. CalBio redirected focus to a heart failure treatment. This decision preceded successful GLP-1 development by other companies by a decade. Novo Nordisk later succeeded with GLP-1 after research starting in 1992.
- oezi 2y agoI guess they were aware how terrible and unpopular injections are for patients. These weren't the days of micro needles...
- layla5alive 2y agoSource/elaboration?
- oezi 2y agoThis is just related that needle pens weren't available in the eighties. So people still were using single disposable syringes with needles which is more painful than using pens with micro needles which became available later.
- brianleb 2y ago>>how terrible injections are for patients What is this belief founded upon? Disposable syringes and detachable needles have been around for over 50 years. We had 6mm needles in the 80s. Evolution of Insulin Delivery Devices https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261311/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261311/
- oezi 2y agoThis was just my understanding from seeing my grand-father 40 years ago having to drop his pants to use insulin syringe + needle, to the use today where you can lift your shirt and use a insulin pen in a couple of seconds.
- Vecr 2y agoThe infection risk is real. What's the relative risk increase regarding death with (with, not from) Hepatitis B infection (not diagnosis, infection) between people who've never injected themselves with anything and injection drug users?
- connicpu 2y agoPersonally I don't understand why so many people are so terrified of needles. Subcutaneous injection is so straightforward, even filling up the single use syringes yourself. I've done that once a week for the past nearly 7 years. But still, from talking with other people who use similar pharmaceuticals to me, so many of them are terrified of needles to the point they choose less effective routes of administration, even though they wish they could have the benefits of the injection route.
- trogdor 2y ago>I don't understand why so many people are so terrified of needles. The fear associated with specific phobias is by definition extreme, unreasonable, and irrational. If you could understand it rationally, it wouldn’t be a phobia.
- Ekaros 2y agoPersonally I just don't particularly enjoy that type of pain... The type I associate with needles.
- johntb86 2y agoMaybe people just don't realize how little pain you can feel with a needle. I switched from the old formulation of humira to the new one (smaller needle and no citrate) and the difference is night and day. Before, I was dreading it every time (though objectively it didn't hurt that much), and after I sometimes don't even feel the needle.
- mannyv 2y agoBack then people would have gone to the doctor’s office for the injection. They would have done that because it wasn’t quite pay-for-service back then.
- renewiltord 2y agoIt's been 34 years, so the original Pfizer patents are invalid and can just be copied? Clearly the primary factor in inability to do that has to be regulation in bringing drug to market, right?
- jayzalowitz 2y ago[flagged]
- Pet_Ant 2y agoThis is tragic when you think about all the people that died of obesity in the mean time. By now, the patent would have expired. Many more people would have survived Covid.
- Someone1234 2y agoThe patent thing in particular. The drug companies are currently charging $1000 per MONTH which is an unimaginable amount of money. Therefore, a lot of people who would otherwise benefit (e.g. obese, prediabetes) simply won't have the option. Unclear to me who has $12,000 extra they can spend on a non-immediate life-saving medication like these. There is technically market competition (wegovy vs zepbound), but surprisingly they all are charging $1K/month with a "discount card" which can be withdrawn at any time, and even that still makes is $6K/year. Currently, many people are benefiting via legal compounding from safe US licensed pharmacies due to the shortages/FDA shortage list, but that route is very soon going to be closed. Then back to $1K/month Vs. $1K/month.
- maxdemarzi 2y agoIt’s $275 a month plus $99 every 6 months at SlimDownRX. The compounded pharmacies are helping.
- fnord77 2y ago$39/month from the top chinese vendors
- maxdemarzi 2y agoTell me more…
- deleted 2y ago[deleted]
- Someone1234 2y ago
- coderintherye 2y ago>MetaBio went down because there were mistaken ideas about what was possible and what was not in the realm of metabolic therapeutics, and because proper corporate structure and adequate capital are always issues when attempting to survive predictable setbacks Like many startup failures, funding issues and corporate structure were more pivotal than the progress made on the actual problem.
- Mistletoe 2y agoObesity was about 17% in the USA in 1990 and is now at an incredible 40%. One wonders how many lives were lost by abandoning this in 1990.
- LarsDu88 2y agoWell, one could argue obesity has as much to do with deregulating the advertising of sugary cereals as a breakfast food for children in the 1980s as the non-existence of a $10,000+ shot that alters human metabolism!
- rootusrootus 2y agoLook at the historical rate of obesity in Europe. Following the same trajectory as the US, as far as I can tell. Does deregulating advertising of sugary cereals also explain that?
- cassepipe 2y agoAdvertising probably not but the simple availability of ever sweeter cheap products and with time their integration in people's diet is a strong candidate. Especially since sugar is way less good than say fat at provoking the feeling of satiation (I can think only of evolutionary explanations for that, available sweet food in the wild, think fruits, are not very nutritive, especially ones not selected by humans over time)
- oezi 2y ago> surgary cereals What else are kids eating these days for breakfast?
- jajko 2y agoWhatever you teach them to eat. But parents are often lazy, its supremely easier to buy addictive paper boxes and be done rather than wake up 10 minutes earlier (or 2) and cook or prepare something quick and healthy. Depends also where you live, US its exactly as we discuss, ie France or Switzerland its a completely different world, and its immediately obvious on people too. This approach also permeates many aspects of society. Kids also imitate what they see in parents, both good and bad. No point preaching healthy lifestyle if one is obese and spends hours daily in front of TV eating junkfood. Also, back in 80s I had maybe 4 years and I knew very well sweet stuff is bad for one's health, it was always as obvious as ie that cigarettes were very harmful and highly addictive. I love how many folks desperately try to throw blame on literally anybody, anything for their failures in life, rather than taking a cold hard look at the mirror and accepting one's own failures, as a parent but also generally as human in this case. Sure, it makes life with oneself a bit easier, instead of huge instant dose of misery and self-disappointment its slowly dripping through the cracks of illusions for the rest of their lives and people love feeling like a victim, but it very effectively prevents actually fixing anything. So sure, lets blame sugar industry (which is doing exactly what all other businesses do - sell to as many people as possible), lets blame tobacco industry or wine producers for people's failures. Lets wait till politicians will sweep away all obstacles and traps from our lives, of course that's a reasonable expectation. Anything but throwing away that 3rd cupcake or starbucks latte.
- ClarityJones 2y ago> Though substantial progress was being made, Pfizer decided to pull support ... [t]he “gliptin” class of drugs peaked at annual revenues of around $10 billion and remains a major oral therapy for type 2 diabetes.
- ClarityJones 2y ago> Pfizer found other routes to remain successful (some, such as their mRNA COVID19 vaccine, also in-licensed from smaller companies). > Even the biggest blockbusters can be dismissed ... by ... ambitious people, ... because ... ideas of how the market will react... . > These same dynamics are undoubtedly playing out today [seemingly referring to previous statements on their COVID-19 vaccine], and it will likely take decades to determine just how costly some of today’s mistakes will prove to be.
- nrb 2y ago> then the implication is that they released the mRNA vaccine because it too would increase disease (and thus avenues for profitability) Sure, a disease that kills a patient very quickly is bad for business. Better for them to be alive and fall ill later on from a laundry list of profitable ailments.
- sweeter 2y agoThe problem with corporate driven drug development is on full display here, they are treating drugs (and by extension, human lives) like investors treat tech startups. It really pisses me off when people say that this drives innovation. The majority of corporate research money goes into patent extension methods (like slightly tweaking the delivery method, or slightly tweaking the forumal ala insulin being released as a free medicine, but costing thousands of dollars a month because of "evergreen" patent extension from corporate pharma companies) and on the other hand most novel compounds come from public research paid by taxpayers. Of which is then sold back to us by coporate pharma companies that buy that research. There is an entire established pipeline, these researchers have no other options than to sell their research papers and findings to companies. It is disgusting on every level and indefensible... especially for the country that pays more than any OEC nation for healthcare, and has worse health outcomes than the majority of extremely impoverished "3rd world" countries. It kills millions every year, and is extremely shameful. It is the biggest embarrassment conceivable
- llamaimperative 2y agoYou should read more about the journey from novel molecule (basic science, generally publicly funded research) to a commercialized drug. It is obscenely hard, expensive, and risky to get a drug — even one that works really well — to market. It’s much harder when you factor in lack of knowledge ahead of time about which molecules in your portfolio actually work. IMO there should be some structure for taxpayers/grant funding agencies to get paid royalties on successful drug programs, but you wildly wildly misunderstand what the hard parts of drug development are. It’s not publishing papers about molecules that do things in Petri dishes.
- siliconc0w 2y agoThe catastrophic failure of FenPhen also cooled the industry's interest in obesity medication. Part of the problem is that it is so slow and expensive to bring a drug to market, which encourages risk aversion. It'd be interesting if we found better regulatory and financial engineering strategies here. There is a gigantic hidden graveyard of people who have died due not having access to medications that could have been produced and approved (which may have even been massively profitable) but were it just didn't make sense to try with today's incentives. Maybe FDA works in classes where class 0 is entirely experimental and only available to terminal patients, class 1 is shown to be safe in animals and approved only for extreme cases, class 2 evidence of safety in humans and some evidence of efficacy, and class 3 is what we have today.
- Spooky23 2y agoThat just pushes the moral hazard down to the providers and patients. Given how big the industry is that peddles mostly bullshit vitamins and supplements, I think society is best served by a conservative FDA.
- tgsovlerkhgsel 2y agoClasses 0-2 could be experimental, non-commercial approvals that can be used as stepping stones to get long term data but not sold for profit.
- carlmr 2y ago>not sold for profit. The only way to ensure no profit would be to provide them for free. Which, granted, may be good still for the pharmaceutical companies to lessen the costs for approvals, but Hollywood accounting makes it impossible to have any price depend on profits, because profits are more an accounting fantasy than a fact.
- selimthegrim 2y agoRing 0 for drugs?
- 2y ago
- hilux 2y agoThat article could be greatly shortened without losing any useful content. The author seems to be guilty of resulting, i.e. judging a decision by its ultimate outcome, rather than by the quality of the decision-making, considering knowledge and constraints at that time.
- ck2 2y agoAlso they've noticed oddly GLP-1 seems to prevent people from dying of covid Doesn't prevent infection but rather death from it https://www.nytimes.com/2024/08/30/health/wegovy-covid-deaths.html https://www.nytimes.com/2024/08/30/health/wegovy-covid-death... https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007
- brianleb 2y agoGLP-1 => weight loss => decreased obesity, improved cholesterol, improved blood pressure, improved glucose control, etc. etc. => better survival rates (all causes) There is no presumed clinically relevant mechanism for GLP-1s to be protective specifically against COVID death. It is simply protective against all death, of which COVID is a type. Healthier people are less likely to die, statistically. The same benefit can be (and is being) said about GLP-1s and heart attacks, heart failure, stroke, kidney failure, etc.
- wswope 2y agoRather arrogant of you to spew forth unfounded conjecture without even bothering to skim the high-level details of a six paragraph article. > the protective effect occurred immediately — before participants had lost significant amounts of weight. > the participants taking the drug were not healthier than the others, said Dr. Harlan Krumholz, a cardiologist at Yale and the editor in chief of the journal.
- brianleb 2y agoI understand how you came to your conclusion, however what you are quoting is journalism (and it is factually incorrect). I read the actual peer reviewed article. The patients in the COVID group, _when they got COVID_ had already begun losing significant amounts of weight. The NYT article is 100% incorrect on this matter. See: >>The change in weight between randomization and reported COVID-19 in patients who died of COVID-19 according to treatment was −6.4 kg in the semaglutide group vs −0.9 kg in the placebo (P < 0.001) group and −8.4 kg vs −1.25 kg (P < 0.001), respectively, in patients who did not die. They go on to say that there is a correlation between obesity and adverse COVID outcomes: >>There was an associated increased risk of respiratory decompensation and mortality in patients with COVID-19 and obesity16,17 and plausible biologic hypotheses associating obesity with adverse COVID outcomes, including impaired respiratory status, lower cardiometabolic reserve, or immune hyperreactivity or dysregulation.18 And they double down on the fact that the patients absolutely had weight loss at time of COVID. >>Accordingly, it is plausible that the decreased risk of infectious deaths is caused by weight loss, which was 5 kg greater in patients assigned to semaglutide compared to placebo by 1 year, the average time to COVID-19 diagnosis after randomization. I will leave you with the note that nowhere in the journal article do they make any claims whatsoever about semaglutide's effect on COVID outcomes. They exclusively discuss outcomes as related to metabolic health. Semaglutide is a means to an end. The means is weight loss. The end is better health.
- jmount 2y agoIt goes in phases. Anything other than pill use to be a hard no, but now we see injections moving beyond just vaccines. I've also heard from a friend that large pharma internal R&D is "pretty much just cancer for now."
- brcmthrowaway 2y agoCould this be true for LK99
- adamontherun 2y agoAcquired had a great episode earlier this year that really connects with this. They talked about how Novo Nordisk stuck with GLP-1 research for decades, even when it didn’t seem like a sure thing. A big part of that was Mads Krogsgaard Thomsen, who pushed for GLP-1 research at Novo even when he faced a lot of skepticism and wasn't always treated well for it. Compare that with MetaBio—mentioned in the study—where Pfizer pulled the plug early and missed the boat entirely. Novo’s persistence, especially Thomsen's, led to Ozempic and Wegovy
- unavoidable 2y agoSo much of this is hindsight bias though. There were no shortage of people with ideas and companies pursuing obesity drugs through a number of different pathways. Only in hindsight does it seem "genius" that Thomsen persisted and succeeded where nobody else did. But there are dozens, hundreds, of other smart people who were pursuing other pathways who did just as much stubborn work but didn't get a result. That's just pharmaceuticals. Take, for example, another high profile disease - Alzheimer's. First there was the beta amyloid theory, then there was the p. gingivalis theory (this one was talked about so highly on this very forum, but ended in an equally high profile failure* of a pivotal clinical trial by Cortexyme). Now there are viral and metabolic theories. Each of these theories have a few dozen companies and armies of PhDs stubbornly pursuing a miracle drug, but so far it remains elusive. * We also like to talk about "failures" of clinical trials, which is technically correct language, but evokes in the public imagination the wrong idea. A clinical trial failure doesn't mean there was something wrong with the idea or process (long before it ever gets there, a drug candidate would have been proven to be very effective in lab tests and animals). It's just that 90% of clinical trials don't end up working due to complex disease pathways and numerous unknown factors. It would help if we talked about "negative proofs" (i.e. proving something doesn't work is also valid), but it's not quite as catchy.
- ZoomerCretin 2y ago> First there was the beta amyloid theory First? Isn't the beta-amyloid cabal still blocking all Alzheimer's research unless the researchers find a way to even tangentially support that long disproven theory?
- light_hue_1 2y agoSince this is YC, it's worth looking at this from the perspective of a failed startup that made several mistakes. In particular, the authors take the view that Pfizer killed their startup. But buried on page 333 is the real reason. And if you're going to start something, this is worth learning from. The founders gave up their ability to control their company when they agreed to become a wholly owned subsidiary from day 1. There was no need for that. And no one would ever tell you to do this today. This was done to be nice and collegial, something that broke down the moment money was involved. The company they created this fatal alliance with had other priorities, their own drug development pipeline. Then they got investors who were profiting from the status quo, and for whom a new drug didn't look great. But the real reason is that the founders half-assed it. None of them left their academic jobs. They didn't have any skin in the game. Oh well, they walked away with a little money. Had the founders done what YC tells you to do, commit, this never would have happened. (bottom of page 333) The whole article blames Pfizer and others for the failure of the startup. But it's really this last point that was the determining factor. The authors say there were confused by the buyout and just took it to move on. There would have been no confusion and no buyout if they were committed to the startup. Even if you have the right idea, even if you are the right person in the right place, even if you're about to break through and change the world, you can fail if you don't commit.